Navigation Links
A Balanced Risk-Benefit Profile Will Propel Orexigen/Takeda's Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
Date:11/6/2013

BURLINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that novel emerging agents will experience steady uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe and well-tolerated weight-loss drugs. However, none of the emerging therapies are set to dominate the space owing to historical safety concerns that have fostered a cautious attitude among physicians and regulatory authorities, particularly in markets outside the United States.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Obesity finds that Orexigen/Takeda's Contrave will become the most widely used emerging therapy due to the fact it offers the best available balance of efficacy and safety among the competing therapeutic entities. A 3.0 mg formulation of Novo Nordisk's Victoza will become the sales leader over the 2012-2022 forecast period, owing to its premium price combined with physician familiarity and the additional metabolic benefits the drug provides. The U.S. launches of Vivus's Qsymia and Arena Pharmaceuticals/Eisai's Belviq in 2012 and 2013, respectively, have both been met with modest uptake, suggesting that historical safety issues associated with antiobesity agents still weigh on the minds of physicians. European and Japanese physicians will also have new treatments available from early in the forecast period, although they will continue to have fewer options from which to choose than their U.S. counterparts.

Decision Resources forecasts that the obesity drug market will grow more than fivefold over the next decade to exceed $2.5 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan; market growth in the United States will be the predominant driver, overall. Novel agents that are forecast to launch over the next decade are expected to capture 91 percent of the obesity market in 2022. Increasing recognition of the medical importance of obesity and the high prevalence of the disease will drive continued demand for safe, efficacious and well tolerated weight-loss therapies.

"There is a great unmet need in the obesity market for agents that can induce satisfactory weight loss; a safe and well tolerated treatment filling the void between the efficacy offered by surgery and that offered by diet, exercise and behavioral modifications has not yet emerged," said Decision Resources Analyst Dr. Tim Blackstock, M.B. Ch.B.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
2. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
3. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
4. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
7. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
8. Bioabsorbable Stents - Global Strategic Business Report - 2013 Profiles 16 Companies inside the Market
9. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
10. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
11. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced ... presence offers quick and easy access to essential information that offers a more ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and commercialization, has just released a new white paper discussing the benefits ... than ever about medical device, pharmaceutical, and combination product organizations making sure ...
(Date:9/20/2017)... ... ... Compliancy Group is proud to announce that its proprietary ... long-time client pass their Department of Health and Human Services (HHS) Office for ... the help of the Compliancy Group's Audit Response Program™, not a single client ...
(Date:9/20/2017)... ... 20, 2017 , ... The Centers for Medicare and Medicaid Services (CMS) stated ... to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments ... complimentary webinars on October 17, 2017 at 2 P.M. EST and uncover how ...
(Date:9/20/2017)... ... 20, 2017 , ... “RECYCLED Ezekiel's Plan for Freedom from ... from ADDICTION” is the creation of published author, Bill Miller. Bill Miller ... services, including more than a decade of addiction to prescription drugs. He ...
Breaking Medicine News(10 mins):